Donald Trump’s 100% Pharma Import Tariff: India Escapes Immediate Hit But Long-Term Risks Remain
- Posted on April 3, 2026
- By The Times of India
- 490 Views
In brief
Trump's proposed 100% pharmaceutical import tariff presents a complex scenario for India's generic drug industry. While immediate exemptions appear likely for critical medications, the policy signals potential long-term disruption in US-India pharmaceutical trade. Indian manufacturers, who supply nearly 45% of American generic drugs, face uncertain regulatory environments and possible supply chain restructuring. The tariff could reshape global pharma supply chains and increase medication costs for American consumers.
